Research reviewEffects of Adipocyte-Derived Cytokines on Endothelial Functions: Implication of Vascular Disease
Introduction
Atherosclerosis is a disease process that starts in fetal life [1] and is associated with a significant morbidity and mortality. Leading predisposing factors include hyperlipidemia, cigarette smoking, hypertension, obesity, and diabetes. Type 2 diabetes is closely associated with obesity and is caused by a relative resistance to insulin, which has recently emerged as a significant vascular hormone with important links to the pathophysiology of atherosclerotic vascular disease [2].
Recent studies have transformed our thinking about the adipocyte. It is no longer viewed as a passive energy storage tissue; instead, it has been recognized to produce a number of metabolically and hormonally active substances, collectively called adipokines or adipocytokines [3]. These adipokines consist of polypeptides but also nonprotein factors that are known to affect different functional categories including immunity function (complement factors and haptoglobin), endocrine function (leptin, sex steroids, and various growth factors), metabolic function (fatty acids, adiponectin, and resistin), and cardiovascular function (angiotensinogen and plasminogen activator inhibitor-1). Adiponectin, leptin, and resistin may have synergistic or competitive activity to insulin. Insulin resistance is an important factor for the development of coronary heart disease, supported by studies in animal models [4] and humans [5]. Therefore, these investigations have the potential to provide useful insight into the pathogenesis of vascular disease.
In this review, we present the current understanding of the complex role of the adipocyte-derived hormones leptin, adiponectin, and resistin on the endothelial cell function and the pathogenesis of atherosclerotic vascular disease. Mechanisms of action and data from animal and human studies, as well as controversies surrounding their function, are discussed.
Section snippets
Leptin
Leptin (from the Greek word leptos meaning thin) was identified by positional cloning in 1993 [6] as a key molecule in the regulation of body weight and energy balance. Subsequent research has revealed that the effect of leptin is not restricted to appetite and food intake. Leptin is a pleiotropic molecule with a broad variety of different biological actions, including reproductive function, regulation of the hypothalamic-pituitary-adrenal (HPA) axis, glucose and insulin metabolism, lipolysis,
Adiponectin
Human adiponectin was isolated from the plasma as gelatin binding protein of 28 kDa [49]. It contains 244 amino acid residues and consists of a 20-residue signal sequence, an N-terminal region without homology to any known proteins, a collage-like region, and a C-terminal globular domain. Under normal conditions, adiponectin gene is expressed almost exclusively in the adipose tissue. However, adiponectin mRNA appears in hepatocytes after treatment with carbon tetrachloride or IL-6 [50, 51].
Resistin
Resistin is a member of a newly discovered family of cysteine-rich secretory proteins called “resistin-like molecules” (RELM) or “found in the inflammatory zone” (FIZZ). It was initially discovered in a screen to identify potential targets of the thiazolidinedione (TZD) class of insulin sensitizers in 3T3-L1 adipocytes [61]. Resistin is encoded by the Retn gene, and is secreted as a disulfide-linked dimer [62]. In mice, the retn gene is expressed almost exclusively in white adipose tissue and
Summary
The identification of adipokines is intriguing from both a theoretical and clinical point of view. There are several lines of evidence to support the notion that at least the three adipokines discussed above are involved in the pathogenesis of atherosclerotic disease (Fig. 1). As further data from human studies are accumulated, the role of adipokines will continue to evolve. The development of pharmacologic antagonists is a very attractive idea and may have implications for both the treatment
Acknowledgments
This work was supported by National Institutes of Health grants R01 HL61943, R01 HL65916, R01 HL60135, and R01 HL72716 (C. Chen); R21 AI49116 (Q. Yao); R01 HL75824 (Lumsden); and K08 HL076345 (Lin).
References (72)
- et al.
Troglitazone suppresses intimal formation following balloon injury in insulin-resistant Zucker fatty rats
Atherosclerosis
(1998) - et al.
Effects of troglitazone on frequency of coronary vasospastic-induced angina pectoris in patients with diabetes mellitus
Am. J. Cardiol.
(1999) - et al.
Leptinlinking adipocyte metabolism with cardiovascular and autoimmune diseases
Prog. Lipid Res.
(2004) - et al.
Does leptin cause functional peripheral sympatholysis?
Am. J. Hypertens.
(2001) - et al.
Potential role of leptin in angiogenesisleptin induces endothelial cell proliferation and expression of matrix metalloproteinases in vivo and in vitro
Exp. Mol. Med.
(2001) - et al.
Leptin induces mitochondrial superoxide production and monocyte chemoattractant protein-1 expression in aortic endothelial cells by increasing fatty acid oxidation via protein kinase A
J. Biol. Chem.
(2001) - et al.
Leptin decreases plasma paraoxonase 1 (PON1) activity and induces oxidative stressthe possible novel mechanism for proatherogenic effect of chronic hyperleptinemia
Atherosclerosis
(2003) - et al.
C-reactive protein in young, apparently healthy menassociations with serum leptin, QTc interval, and high-density lipoprotein-cholesterol
Metabolism
(2003) - et al.
High plasma immunoreactive leptin level in essential hypertension
Am. J. Hypertens.
(1997) - et al.
Modulation of circulating leptin levels by its soluble receptor
J. Biol. Chem.
(2001)